| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/19/2002 | WO2002072003A2 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002053533A3 Kappa opioid receptor ligands |
| 09/19/2002 | WO2002050070A3 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 09/19/2002 | WO2002036140A3 Use of a preparation of cimicifuga racemosa |
| 09/19/2002 | WO2002036123A3 New treatments for restless legs syndrome |
| 09/19/2002 | WO2002033096A3 Regulation of human serine-threonine protein kinase |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002030876A3 Cyclic carboxylic acids as integrin antagonists |
| 09/19/2002 | WO2002030409A8 Methods for the treatment of a traumatic central nervous system injury |
| 09/19/2002 | WO2002024695A3 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 09/19/2002 | WO2002024194A9 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 09/19/2002 | WO2002024158A3 Pulmonary delivery in treating disorders of the central nervous system |
| 09/19/2002 | WO2002018341A3 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 09/19/2002 | WO2002014355A3 Novel mitogen activated kinase |
| 09/19/2002 | WO2002014311A3 Urea compounds and methods of uses |
| 09/19/2002 | WO2002002610A3 Secretion and trafficking molecules |
| 09/19/2002 | WO2002002189A3 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 09/19/2002 | WO2001097779A3 Improved injectable dispersions of propofol |
| 09/19/2002 | WO2001085956A3 Lipid metabolism enzymes |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020133019 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition |
| 09/19/2002 | US20020133011 Alcoholism, psychological disorders |
| 09/19/2002 | US20020133010 Epoxidation; quaternization |
| 09/19/2002 | US20020133001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 09/19/2002 | US20020132858 Method for treating sexual disorders |
| 09/19/2002 | US20020132853 Diaryl piperazines and related compounds useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132850 Multilayer tablet for administering a fixed combination of tramadol and diclofenac |
| 09/19/2002 | US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132830 Use of beta 2 bronchodilator drugs |
| 09/19/2002 | US20020132828 N-substituted-4-(m-hydroxyphenyl)piperidine derivated and esters thereof, used to bind a kappa opioid receptor; treating drug addiction |
| 09/19/2002 | US20020132827 Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period." |
| 09/19/2002 | US20020132825 Analgesic combination of oxycodone and celecoxib |
| 09/19/2002 | US20020132824 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction |
| 09/19/2002 | US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/19/2002 | US20020132820 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 09/19/2002 | US20020132811 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| 09/19/2002 | US20020132810 Novel heterocyclic amide derivatives |
| 09/19/2002 | US20020132809 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 09/19/2002 | US20020132802 Cytoprotective polycyclic compounds |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132777 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132754 Producing pharmaceuticals for improving perception, concentration, learning and/or memory. |
| 09/19/2002 | US20020132334 Nucleotide sequences coding preferential polypeptide for use in the treatment of tumors and nervous system disorders |
| 09/19/2002 | US20020132319 Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132009 Entacapone, nitecapone, or salts thereof and croscarmellose sodium to increase the release rate; catechol-O-methyl transferase inhibitors |
| 09/19/2002 | US20020132006 Odor-masking coating for a pharmaceutical preparation |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | US20020131932 Radiopharmaceuticals for diagnosing alzheimer's disease |
| 09/19/2002 | DE10112768A1 New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases |
| 09/19/2002 | DE10112198A1 Substituierte Dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-amine Substituted dimethyl- [1- (1-phenyl-cyclohexyl) -piperidin-3-ylmethyl] -amines |
| 09/19/2002 | DE10112151A1 New 5-(4-(indolyl-alkyl)-piperazino)-benzofuran-2-carboxamides useful e.g. for treating depression, anxiety, psychiatric or cerebral disorders or pain, are 5-HT-1A receptor agonists and 5-HT reuptake inhibitors |
| 09/19/2002 | DE10110953A1 Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten Transdermal therapeutic system for administration of partial dopamine-D2 agonists |
| 09/19/2002 | DE10110754A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10110438A1 Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10058461A1 Substituierte Cyclohexanderivate und ihre Verwendung Substituted cyclohexane derivatives and their use |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2441495A1 Proteins associated with cell growth, differentiation, and death |
| 09/19/2002 | CA2441434A1 Remedies for nerve damages |
| 09/19/2002 | CA2440973A1 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440758A1 Substituted dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-amines |
| 09/19/2002 | CA2440675A1 Composition containing asiasari radix extracts for protecting brain cells and improving memory |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440374A1 A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient |
| 09/19/2002 | CA2440284A1 Ph-dependent nmda receptor antagonists |
| 09/19/2002 | CA2439853A1 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof |
| 09/19/2002 | CA2439702A1 Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof |
| 09/19/2002 | CA2439301A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | CA2438874A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | CA2438868A1 Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2438164A1 Use of preparations containing selenite or selenate |
| 09/19/2002 | CA2437963A1 Therapeutic binding molecules |
| 09/19/2002 | CA2437960A1 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 09/19/2002 | CA2437958A1 Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| 09/19/2002 | CA2437756A1 Nucleic acid-associated proteins |
| 09/19/2002 | CA2437746A1 Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| 09/19/2002 | CA2436083A1 Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders |
| 09/18/2002 | WO2001072710A1 Heterocycle derivatives and drugs |
| 09/18/2002 | EP1241259A1 Peptide having pronociceptive properties |
| 09/18/2002 | EP1241254A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 09/18/2002 | EP1241170A2 Pyrazolopyrimidine derivatives |
| 09/18/2002 | EP1241169A1 Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 09/18/2002 | EP1241168A1 Human NK3 receptor-selective antagonist compounds, process for their obtention and pharmaceutical compositons containing them |
| 09/18/2002 | EP1241113A1 Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| 09/18/2002 | EP1240823A1 N-calcium channel knockout animal |
| 09/18/2002 | EP1240525A2 Sodium channels as targets for amyloid beta |
| 09/18/2002 | EP1240344A1 Replication incompetent herpes viruses for use in gene therapy |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240327A2 Interferon-like molecules and uses thereof |
| 09/18/2002 | EP1240313A2 Homologues of human heparanase and splice variants thereof |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240195A2 Polynucleotides and polypeptides encoded thereby |
| 09/18/2002 | EP1240194A2 Novel human protein kinases and protein kinase-like enzymes |